National Society of Genetic Counselors
Collaborative Group of the Americas on Inherited Colorectal Cancer
Full Text Guideline
Evidence Supporting the Recommendations
Bao F, Panarelli NC, Rennert H, Sherr DL, Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol. 2010 Dec;34(12):1798-804. PubMed
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 Nov 15;58(22):5248-57. [119 references] PubMed
Chang DK, Metzgar D, Wills C, Boland CR. Microsatellites in the eukaryotic DNA mismatch repair genes as modulators of evolutionary mutation rate. Genome Res. 2001 Jul;11(7):1145-6. [10 references] PubMed
Choi MY, Lauwers GY, Hur C, Willett CG, Chung DC. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1584. PubMed
Muller A, Giuffre G, Edmonston TB, Mathiak M, Roggendorf B, Heinmoller E, Brodegger T, Tuccari G, Mangold E, Buettner R, Ruschoff J, German HNPCC Consortium German Cancer Aid (Deutsche Krebshilfe). Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J Mol Diagn. 2004 Nov;6(4):308-15. PubMed
Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009 Jan;11(1):42-65. [133 references] PubMed
Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA, Katabi N, Weiser MR, Paty PB, Temple LK, Nash GM, Wong WD, Offit K, Klimstra DS. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009 Nov;33(11):1639-45. PubMed
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18;96(4):261-8. PubMed
The type of supporting evidence is not specifically stated for each recommendation.
Implementation of the Guideline
An implementation strategy was not provided.
Benefits/Harms of Implementing the Guideline Recommendations
Appropriate use of risk assessment, counseling, and testing for Lynch syndrome
- Genetic cancer risk assessment is an important component of a Lynch syndrome evaluation given that testing can be complex, tumor and molecular results may not be straightforward, and psychosocial issues may arise all of which necessitate involvement of a specialized genetics professional.
- False positive and false negative test results
Rating Scheme for the Strength of the Recommendations
- The guidelines outlined herein are intended only to provide guidance for performing a genetic evaluation for Lynch syndrome (LS). The guidelines were not developed to replace a thorough cancer risk assessment by a qualified genetics professional. Genetic cancer risk assessment is an important component of a LS evaluation given that testing can be complex, tumor and molecular results may not be straightforward, and psychosocial issues may arise all of which necessitate involvement of a specialized genetics professional. As the field of genetics is rapidly evolving, it is critical that all healthcare professionals who evaluate patients for LS remain current on advances in this constantly changing field.
- This practice guideline was developed by members of the National Society of Genetic Counselors (NSGC) and Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC) to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns; including access to and/or delivery of services. This practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within this joint NSGC and CGA-ICC practice guideline reflect scientific and clinical knowledge current as of the time of publication, is only current as of its publication date, and is subject to change without notice as advances emerge.
- In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider's best medical judgment based on the clinical circumstances of a particular patient or patient population. This practice guideline is published by NSGC and CGA-ICC for educational and informational purposes only, and neither NSGC nor CGA-ICC "approves" or "endorses" any specific methods, practices, or sources of information contained herein.
Searches of Electronic Databases
The guideline authors searched via MEDLINE/PubMed for articles from the time period of 1991 to the present. The search terms used were: Lynch syndrome, HNPCC, colon neoplasms, microsatellite instability, immunohistochemistry, MMR genes, endometrial neoplasms, BRAF, MLH1 methylation, MLH1, MSH2, MSH6, and PMS2.
Expert consensus review of relevant medical literature
Published cost analyses were reviewed.
External Peer Review
Internal Peer Review
Identifying Information and Availability
Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, Jasperson K, Kalady MF, Haidle JL, Lynch HT, Palaniappan S, Wise PE, Senter L. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns. 2012 Aug;21(4):484-93. [56 references] PubMed
Not applicable: The guideline was not adapted from another source.
National Society of Genetic Counselors
Authors: Scott M. Weissman, Randall Burt, James Church, Steve Erdman, Heather Hampel, Spring Holter, Kory Jasperson, Matt F. Kalady, Joy Larsen Haidle, Henry T. Lynch, Selvi Palaniappan, Paul E. Wise, Leigha Senter
This is the current release of the guideline.
Electronic copies: Available to subscribers from the Journal of Genetic Counseling Web site.
The following is available:
- Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 2008 Oct;17(5):424-33. Available to subscribers from the Journal of Genetic Counseling Web site.
This NGC summary was completed by ECRI Institute on June 29, 2012. The information was verified by the guideline developer on July 16, 2012.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.
Obstetrics and Gynecology
Advanced Practice Nurses
Allied Health Personnel
Health Care Providers
Psychologists/Non-physician Behavioral Health Clinicians
To provide guidance and a testing algorithm for Lynch syndrome as well as recommendations on when to offer testing
Individuals who have or may be at risk of developing Lynch syndrome
- Tumor analysis on colorectal cancer or endometrial cancers
- Microsatellite instability (MSI)
- Immunohistochemistry (IHC)
- MSI and IHC of affected relative's tumor
- Direct germ line genetic testing
Sensitivity and specificity of genetic and immunohistochemical testing
- Microsatellite instability (MSI) and immunohistochemistry (IHC) tumor analyses should be performed on cancer of the colon and/or rectum (CRC) or endometrial cancers as the first-line testing strategy for any patient being evaluated for Lynch syndrome (LS) (this includes individuals with CRC or endometrial cancer who meet Amsterdam I or II criteria or Bethesda guidelines).
- MSI and IHC tumor analyses are highly sensitive and specific approaches to identify patients and families with LS (Palomaki et al., 2009). Figure 1 in the original guideline document outlines the testing schema for individuals where LS is suspected based on personal and/or family history.
- MLH1 promoter methylation and BRAF V600E mutation testing may help to reduce the number of germline genetic tests needed when IHC reveals absence of MLH1 and PMS2. However, the National Society of Genetic Counselors (NSGC) and the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC) did not find enough data to recommend one test over the other or both concomitantly.
- IHC may occasionally yield atypical results. If IHC reveals absent MLH1 or MSH2 only, consider genetic testing of those genes individually. If IHC reveals loss of more than two mismatch repair (MMR) proteins, consider repeating the IHC analysis. If the results persist or if repeat testing was not performed, consider following the algorithm based on the most likely true results (i.e., if MSH2, MSH6 and MLH1 or PMS2 are all absent, follow the loss of MSH2/MSH6 pathway; if MLH1, PMS2 and MSH6 or MSH2 are all absent, follow the MLH1 and PMS2 pathway). Further, it is worth noting that there is a mononucleotide microsatellite in MSH6 that may cause loss of MSH6 with another MMR germline mutation leading to aberrant IHC staining patterns (Chang et al., 2001; Shia et al., 2009).
- When MSI testing is stable, but IHC shows absence of one or more MMR proteins, clinical judgment should be used to determine whether tumor studies should be repeated or germline genetic testing should be pursued.
- MSI testing should include, at a minimum, the five markers included in the National Cancer Institute (NCI) panel (Boland et al., 1998; Umar et al., 2004).
- MSI and IHC should be performed on pretreated specimens.
- Some data suggest that MSI and IHC (it is possible to get false positive loss of MSH6 expression) results may be affected by neoadjuvant therapy; therefore, if MSI and/or IHC is performed on a treated specimen, results should be interpreted with caution (Bao et al., 2010; Choi et al., 2007).
- MSI and IHC can be technically challenging assays and should be performed in laboratories that have experience with these tests to minimize the possibility of false positive or false negative results (Müller et al., 2004)
- MSI and IHC should be performed, when possible, on an affected relative's tumor when an unaffected patient is being evaluated for LS.
- On occasion, obtaining a tumor tissue block will require a patient to involve other family members (e.g., when the patient is not the person who has cancer) or their healthcare providers to request tissue for testing. Ascertainment of the tissue should be possible in most cases as many hospitals store tissue blocks for at least 10 years.
- While we recognize that some third party payers may not cover MSI and/or IHC analyses on the tumor of a patient's family member(s) (e.g., the family member is deceased), in our expert opinion, we deem testing the family member(s)' tumor is justified because: 1) LS is one of a few hereditary cancer syndromes that has a validated screening test to determine if germline genetic testing is warranted; 2) if an affected family member is living, it is likely that MSI and IHC will be covered by that relative's insurance; 3) a negative germline genetic test for all four MMR genes in an unaffected patient is uninformative; 4) the cost of direct germline genetic testing for each MMR gene ranges from $1000 to $1500, whereas the cost of MSI and IHC together is ~$1000; 5) if IHC is abnormal, additional tumor tests (BRAF and MLH1 promoter methylation) may help determine if germline genetic testing is necessary and if it is warranted, testing can be targeted to one or two genes limiting overall costs; and 6) normal MSI and IHC results on an affected individual would significantly lower the likelihood that LS is the explanation for the cancer in the family and germline genetic testing would most likely not be needed.
- Direct germline genetic testing (refers to both deoxyribonucleic acid (DNA) sequencing and a technology that detects large rearrangements, insertions, deletions and duplications) may be considered on an affected or unaffected patient being evaluated for LS when MSI and IHC testing are not feasible.
- In the event that a tumor block is not available, a family member(s) is not willing or able to participate in testing, there are financial concerns or there is insufficient tissue to do either MSI or IHC testing, when indicated (e.g., high familial risk is present such as Amsterdam criteria), direct germline genetic testing may be considered. It should be noted, however, that negative germline testing in an affected individual who has not had MMR IHC can also be uninformative because there are some individuals with unidentifiable MMR gene mutations that would be followed as having LS based on abnormal IHC.
A clinical algorithm for Lynch syndrome evaluations and testing is provided in the original guideline document.
Institute of Medicine (IOM) National Healthcare Quality Report Categories
Living with Illness
The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.